BioSpace News Archive

Panavance Therapeutics Inc. (“Panavance”) is a new clinical-stage pharmaceutical company created to advance and develop GP-2250, a patented, novel therapeutic for the treatment of cancer and other therapeutic indications.

AlivaMab Discovery Services, LLC, a leader in the discovery of superior antibody-based therapeutics, announced Jane Seagal, PhD, has joined the company as Vice President of Antibody Discovery.

Veristat, a scientific-minded global clinical research organization (CRO), announced today that the Company supported clients in preparing marketing applications for 12% of the 2021 U.S. Food and Drug Administration (FDA) novel drug approvals.

IncellDx, a precision medicine company, today announced the journal Frontiers in Immunology has published a study detailing a framework for understanding the potential mechanism of, and potential treatment for, Post-Acute Sequelae of COVID-19 (PASC), also known as long COVID or long haul COVID.

Extensive research and development of different therapeutic approaches to treat urinary incontinence, advancements in cognitive and behavioral therapy, and increasing prevalence of stress urinary incontinence in women across the globe are some key factors expected to drive market growth.

Genesis Therapeutics, a company pioneering AI technologies to create medicines for patients with severe and unmet medical needs, announced today that Evan Feinberg Ph.D., Genesis Therapeutics CEO and co-founder, will present at the 40th Annual J.P. Morgan Healthcare Conference.

Basilea Pharmaceutica Ltd., a commercial-stage biopharmaceutical company committed to meeting the needs of patients with infectious diseases and cancer, announced the completion of patient enrolment into the phase 3 ERADICATE study.

Evotec SE announced that the Company has expanded its neurodegeneration collaboration with Bristol Myers Squibb with the initiation of discovery and development efforts regarding a new strategy to tackle neurodegenerative diseases including Alzheimer’s through a novel approach to targeted protein degradation.

Sotera Health Company today is providing an update on the Company’s accomplishments and key growth drivers, as well as the current market dynamics related to its businesses.

Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today presents long-term safety and efficacy data from the open-label extension (OLE) of its global Phase 3 MPOWERED non-inferiority clinical trial that compared Mycapssa® (oral octreotide capsules) to long-acting iSRLs for maintenance of biochemical response in patients with acromegaly.